Evermil 5mg Tablet

Breast cancer
Lung cancer
Pancreatic cancer
Kidney cancer
Prevention of organ rejection in transplant patients

The human body shows undesired symptoms after taking Evermil 5mg Tablet. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.

Some of the common side effects of Evermil Tablet are mentioned below:

Fever

Hair loss

Infection

BleedingDizzinessCoughing

Wheezing

Tiredness

Dry mouth

Muscle pain

Excessive thirst

Increased appetite

Serious side effects:

Difficulty breathing and swallowing

Swelling on face, lips, tongue, throat

Severe itching, red rash, raised bumps

As directed by your physician, take this medication for the prescribed duration. Eat it all at once. Avoid chewing, crushing, or breaking it. It is preferable to take Evermil 5 Tablet at a set time, but it can be taken with or without food.

Evermil 5mg Tablet works by stopping the activity of a protein known as a mammalian target of rapamycin (mTOR). This protein is responsible for cell growth and division. Evermil Tablet slows down the growth of cancerous cells by blocking the production of the mTOR protein. It also reduces the size of the tumor and prevents cancer from spreading to other parts of the body.

It is advised not to miss any scheduled dosage of Evermil 5mg Tablet. In case you miss a dose, consult your doctor immediately.

Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

It is advised to use effective birth control ways and avoid pregnancy during the treatment with Evermil 5mg Tablet.

A person should avoid smoking while undergoing treatment with Evermil 5mg Tablet. Smoking may reduce the effectiveness of medicine.

Monitor your blood sugar & pressure, Kidney & Liver function (KFT & LFT), and Heart function at proper intervals after taking Evermil 5mg Tablet.

Swelling of hands, lips, and weight gain are some of the side effects observed after taking Evermil 5mg Tablet. To reduce them, the doctor may suggest some medication.

Skin becomes extremely sensitive after taking Evermil 5mg Tablet. It is advised to cover your skin exposed to direct sun rays and use high SPF sunscreen before going out.

It is advised to avoid taking analgesics/ antacids (medicines used to neutralize the stomach acid) while taking Evermil 5mg Tablet, as it may reduce the effectiveness of the medicine.

Keep your body hydrated as Diarrhea is one of the common side effects experienced after taking Evermil 5mg Tablet. Consult your doctor if it doesn't stop or if blood appears in your stools.

In case you notice symptoms like blurred vision, difficulty breathing, cough & fever, and diarrhea while taking Evermil 5mg Tablet, consult your doctor immediately before these symptoms become severe.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Bengueddache, S., Cook, M., Lehmann, S., Arroyo, D., Togni, M., Puricel, S., & Cook, S. (2024). Ten-year clinical outcomes of everolimus- and biolimus-eluting coronary stents vs. Everolimus-eluting bioresorbable vascular scaffolds—Insights from the EVERBIO-2 trial. Frontiers in Cardiovascular Medicine, 11(4), 1426348.

Bingqi Zhuang, Chongning Zhong, Yuting Ma, Ao Wang, Hailian Quan, Lan Hong (2024). Innovative Therapeutic Strategies for Myocardial Infarction Across Various Stages: Non-Coding RNA and Stem Cells, International Journal of Molecular Sciences, 10.3390/ijms26010231, 26, 1, (231).

De Simone, P., Precisi, A., Lai, Q., Ducci, J., Campani, D., Marchetti, P., & Gitto, S. (2024). Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers, 16(7), 1243

Fort-Casamartina, E., Pernas, S., Otero, S., Mate, P., Gonzalo, N., Narváez, S., Rigo-Bonnin, R., Padró-Miquel, A., Teulé, À., Garcia del Muro, X., Peiró, I., Arribas, L., Esteve, A., Gonzalez, A., Rey, M., Clopés, A., Fontanals, S., & Muñoz, C. (2025). Everolimus Through Plasmatic Concentrations in Cancer Patients: Prospective Longitudinal Observational Multicentric Study (DIANA-1 Project). Journal of Clinical Medicine, 14(1), 145.

Gulati S, Tangen C, Ryan CW, et al. (2024) Adjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open.7(8):e2425288.

Powles, T., Choueiri, T. K., Albiges, L., Peltola, K., de Velasco, G., Burotto, M., Suarez, C., Ghatalia, P., Iacovelli, R., Lam, E. T., Verzoni, E., Gümüş, M., Stadler, W. M., Kollmannsberger, C., Melichar, B., Venugopal, B., Gross‑Goupil, M., Poprach, A., De Santis, M., Rizzo, M., Shinde, R., Saretsky, T. L., He, L., Perini, R. F., & Vickery, D. (2025). Health‑related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK‑005): Patient‑reported outcomes from a randomized, open‑label, phase 3 trial. Lancet Oncology, 26(4), 491–502.

Saliba F, Duvoux C, Dharancy S, Dumortier J, Calmus Y, Gugenheim J, Kamar N, Salamé E, Neau-Cransac M, Vanlemmens C, Durand F, Pageaux GP, Hardwigsen J, Benkhatar Y, Derquenne F, Conti F.(2025) Five-year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study. Liver Int. Nov;42(11):2513-2523.

Taboada, R. G., Brito, A. B., Silva, A. L., Weschenfelder, R. F., & Riechelmann, R. P. (2024). The Efficacy of a Lower Dose of Everolimus in Patients with Advanced Neuroendocrine Tumors. Cancers, 16(22), 3773.